{"DataElement":{"publicId":"3447310","version":"1","preferredName":"Uterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for uterine adenosarcoma.","longName":"3444927v1.0:3447098v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3444927","version":"1","preferredName":"Uterine Adenosarcoma Stage Grouping","preferredDefinition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ._A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"3444913v1.0:2230143v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3444913","version":"1","preferredName":"Corpus Uteri Adenosarcoma","preferredDefinition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.:A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","longName":"C12316:C9474","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corpus Uteri","conceptCode":"C12316","definition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenosarcoma","conceptCode":"C9474","definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFC61B5-2B81-B731-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFC61B5-2C67-B731-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3447098","version":"1","preferredName":"Uterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma. -- 2004_A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3447098v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"I","valueDescription":"Stage I Uterine Sarcoma","ValueMeaning":{"publicId":"3447099","version":"1","preferredName":"Stage I Uterine Sarcoma","longName":"3447099","preferredDefinition":"Stage I includes: T1, N0, M0.  T1: Tumor limited to the uterus.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Uterine Sarcoma AJCC v7","conceptCode":"C8258","definition":"Stage I includes: T1, N0, M0.  T1: Tumor limited to the uterus.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-317D-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-3195-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Uterine Sarcoma","ValueMeaning":{"publicId":"3447100","version":"1","preferredName":"Stage IA Uterine Sarcoma","longName":"3447100","preferredDefinition":"Stage IA includes: T1a, N0, M0.  T1a: For leiomyosarcoma and endometrial stromal sarcoma: tumor 5 cm or less in greatest dimension.  For adenosarcoma: tumor limited to endometrium/endocervix.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Uterine Sarcoma AJCC v7","conceptCode":"C87132","definition":"Stage IA includes: T1a, N0, M0.  T1a: For leiomyosarcoma and endometrial stromal sarcoma: tumor 5 cm or less in greatest dimension.  For adenosarcoma: tumor limited to endometrium/endocervix.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-31A0-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-31B8-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Uterine Sarcoma","ValueMeaning":{"publicId":"3447101","version":"1","preferredName":"Stage IB Uterine Sarcoma","longName":"3447101","preferredDefinition":"Stage IB includes: T1b, N0, M0.  T1b: For leiomyosarcoma and endometrial stromal sarcoma: tumor more than 5 cm in greatest dimension.  For adenosarcoma: tumor invades to less than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Uterine Sarcoma AJCC v7","conceptCode":"C87133","definition":"Stage IB includes: T1b, N0, M0.  T1b: For leiomyosarcoma and endometrial stromal sarcoma: tumor more than 5 cm in greatest dimension.  For adenosarcoma: tumor invades to less than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-31C3-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-31DB-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IC","valueDescription":"Stage IC Uterine Sarcoma","ValueMeaning":{"publicId":"3447103","version":"1","preferredName":"Stage IC Uterine Sarcoma","longName":"3447103","preferredDefinition":"Stage IC includes: T1c, N0, M0.  T1c: For adenosarcoma: tumor invades more than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  Stage IC does not apply for leiomyosarcoma and endometrial stromal sarcoma.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IC Uterine Sarcoma AJCC v7","conceptCode":"C87134","definition":"Stage IC includes: T1c, N0, M0.  T1c: For adenosarcoma: tumor invades more than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  Stage IC does not apply for leiomyosarcoma and endometrial stromal sarcoma.  (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-31E9-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-3202-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Uterine Sarcoma","ValueMeaning":{"publicId":"3447104","version":"1","preferredName":"Stage II Uterine Sarcoma","longName":"3447104","preferredDefinition":"Stage II includes: T2, N0, M0.  T2: Tumor extends beyond the uterus, within the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Uterine Sarcoma AJCC v7","conceptCode":"C8259","definition":"Stage II includes: T2, N0, M0.  T2: Tumor extends beyond the uterus, within the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-320C-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-3224-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Uterine Sarcoma","ValueMeaning":{"publicId":"3447105","version":"1","preferredName":"Stage IIIA Uterine Sarcoma","longName":"3447105","preferredDefinition":"Stage IIIA includes: T3a, N0, M0.  T3a: Tumor infiltrates abdominal tissues, one side. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Uterine Sarcoma AJCC v7","conceptCode":"C87135","definition":"Stage IIIA includes: T3a, N0, M0.  T3a: Tumor infiltrates abdominal tissues, one side. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-322F-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-3247-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Uterine Sarcoma","ValueMeaning":{"publicId":"3447106","version":"1","preferredName":"Stage IIIB Uterine Sarcoma","longName":"3447106","preferredDefinition":"Stage IIIB includes: T3b, N0, M0. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Uterine Sarcoma AJCC v7","conceptCode":"C87137","definition":"Stage IIIB includes: T3b, N0, M0. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-3252-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-326A-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Uterine Sarcoma","ValueMeaning":{"publicId":"3447107","version":"1","preferredName":"Stage IIIC Uterine Sarcoma","longName":"3447107","preferredDefinition":"Stage IIIC includes: T1-T3, N1, M0.  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Uterine Sarcoma AJCC v7","conceptCode":"C87138","definition":"Stage IIIC includes: T1-T3, N1, M0.  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-3275-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-328D-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Uterine Sarcoma","ValueMeaning":{"publicId":"3447108","version":"1","preferredName":"Stage IVA Uterine Sarcoma","longName":"3447108","preferredDefinition":"Stage IVA includes: T4, Any N, M0. T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Uterine Sarcoma AJCC v7","conceptCode":"C87140","definition":"Stage IVA includes: T4, Any N, M0. T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-3298-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-32B0-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Uterine Sarcoma","ValueMeaning":{"publicId":"3447109","version":"1","preferredName":"Stage IVB Uterine Sarcoma","longName":"3447109","preferredDefinition":"Stage IVB includes: Any T, Any N, M1.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Uterine Sarcoma AJCC v7","conceptCode":"C87144","definition":"Stage IVB includes: Any T, Any N, M1.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-32BB-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-32D3-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"},{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-32F1-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3447097","version":"1","preferredName":"Uterine Corpus Sarcoma Adenosarcoma American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma. -- 2004:A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3447097v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Sarcoma","conceptCode":"C6339","definition":"A malignant mesenchymal neoplasm arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Adenosarcoma","conceptCode":"C9474","definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-3154-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-3165-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"COOPERM","dateModified":"2012-05-07","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3444895","version":"1","longName":"Corpus Uteri Sarcoma","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"5777531","version":"1","longName":"Uterine Adenosarcoma","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"BF0F910D-4BD8-0D12-E040-BB89AD43049B","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}